<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811343</url>
  </required_header>
  <id_info>
    <org_study_id>P070310</org_study_id>
    <secondary_id>2008-A00744-51</secondary_id>
    <nct_id>NCT00811343</nct_id>
  </id_info>
  <brief_title>Impact of New Immunological Diagnosis Tests of Latent Tuberculosis Before Anti TNF Therapy</brief_title>
  <acronym>ETAT</acronym>
  <official_title>Impact of New Immunological Diagnosis Tests of Latent Tuberculosis in Adults Patients Who Need Anti TNF Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis is a current infection during anti TNF therapy. After infectious contact, some&#xD;
      patients will develop tuberculosis and some will only be infected without symptoms, they have&#xD;
      Latent Tuberculosis Infection (LTBI) wich can reactivate later. In order to prevent this&#xD;
      tuberculosis reactivation, LTBI diagnosis screening is preconised in patients who need anti&#xD;
      TNF therapy. This diagnosis is made till now by the tuberculin skin test (TST) but this test&#xD;
      is not specific of TB. New blood tests (QFTB-G and T-SPOT.TB) specific to MTB infection are&#xD;
      now available.&#xD;
&#xD;
      The primary endpoint of this study is the evaluation of the theoric therapeutic impact of the&#xD;
      use of new tests for diagnosis of LTBI in patients before anti TBF therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description :&#xD;
&#xD;
      Principal outcome: Therapeutic impact of the use of new tests for diagnosis of LTBI in&#xD;
      patients before anti TBF therapy&#xD;
&#xD;
      Secondary outcomes :&#xD;
&#xD;
        -  medico-economic impact of replacement of TST by QFTB-G and T-SPOT.TB tests in LTBI&#xD;
           screening in patients before anti TNF therapy.&#xD;
&#xD;
        -  concordance of QFTB-G and T-SPOT.TB tests results with TST&#xD;
&#xD;
        -  Concordance between QFTB-G and T-SPOT.TB tests and evaluation of indetermined tests.&#xD;
&#xD;
        -  concordance of QFTB-G and T-SPOT.TB tests results with patient disease.&#xD;
&#xD;
        -  concordance of QFTB-G and T-SPOT.TB tests results with TST in patients with LTBI&#xD;
           determinated by clinical or radiological observation&#xD;
&#xD;
        -  Impact of geographical, disease and treatment in patients with LTBI determinated by&#xD;
           clinical or radiological observation&#xD;
&#xD;
        -  Identify the original characteristic and maximal impact therapeutic of QFTB-G and&#xD;
           T-SPOT.TB test&#xD;
&#xD;
      Analysed criteria :&#xD;
&#xD;
        -  therapeutic impact&#xD;
&#xD;
        -  Patients percentage with different therapeutic outcome based on usual recommendations&#xD;
           medico-economic&#xD;
&#xD;
        -  Medico-economic impact :impact of both tests as early and late cost - efficacy&#xD;
&#xD;
      Statistic :&#xD;
&#xD;
        -  Primary criteria : Percentage of patients for whom therapeutic would have been changed&#xD;
           by QFTB-G and T-SPOT.TB tests results compared to usual diagnosis strategy.&#xD;
&#xD;
        -  Secondary criteria : Concordance of QFTB-G and T-SPOT.TB tests with TST Concordance&#xD;
           between both QFTB-G and T-SPOT.TB tests .&#xD;
&#xD;
           400 patients Timing : inclusions : 1 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic impact</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>medico-economic impact</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">430</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QFTB-G and T-SPOT.TB tests</intervention_name>
    <description>QFTB-G and T-SPOT.TB test before TST</description>
    <arm_group_label>1</arm_group_label>
    <other_name>There are no arms currently listed for this study.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old&#xD;
&#xD;
          -  Patient with rheumatoid arthritis or Ankylosing spondylitis or Crohn's disease&#xD;
&#xD;
          -  Patient without Anti TNF treatment and who need one by infliximab, adalimumab or&#xD;
             etanercept&#xD;
&#xD;
          -  Consent signed&#xD;
&#xD;
          -  Patient with social right&#xD;
&#xD;
          -  Patient who have been examined&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Mariette, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bicêtre hospital</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <last_update_submitted>January 6, 2014</last_update_submitted>
  <last_update_submitted_qc>January 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti TNF Therapy</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Tuberculin test</keyword>
  <keyword>QFTB-G</keyword>
  <keyword>T-SPOT.TB</keyword>
  <keyword>Need anti TNF Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

